Page 38 - Nsclc News Today

Immune checkpoint inhibitors (ICIs) were active and showed similar safety in patients with HIV and cancer to that seen in matched controls.

Mark A. Socinski, MD, executive director at AdventHealth Cancer Institute, shares insight on the cost-effectiveness and utility of biomarker testing in non–small cell lung cancer (NSCLC).

A brief review of the POSEIDON trial, which analyzed durvalumab with or without tremelimumab in combination with chemotherapy in advanced NSCLC.

Key opinion leaders in the field of non–small cell lung cancer management discuss the role of immunotherapy in patients with concomitant KRAS and KEAP1/STK11 mutations.

Experts review data updates on chemotherapy / immunotherapy combination treatments in advanced NSCLC.

Closing their discussion, the panel shares their final thoughts on recent updates in advanced NSCLC and looks to the future of treatment.

A comprehensive discussion on combination chemotherapy + immunotherapy regimens available to patients with advanced non–small cell lung cancer.

Expert oncologist John Heymach, MD, PhD, reviews data from the phase 3 AEGEAN trial following updates presented at the 2023 AACR annual meeting.

Shared insight on the value that molecular testing and PDL1 testing, respectively, have on determining optimal therapy for patients with advanced non–small cell lung cancer.

Compared with first-line immunotherapy or chemotherapy alone, combination chemoimmunotherapy for advanced/metastatic non–small cell lung cancer has significantly higher antineoplastic drug and associated medical costs.